Skip to main content

Table 3 General demographic and clinical data in patients with and without restored circulatory efficiency (CircE)  after AVR

From: Circulatory efficiency in patients with severe aortic valve stenosis before and after aortic valve replacement

  not restored CircE (n = 10) restored CircE (n = 31) p-value
Age (years) 67 ± 7.8 66 ± 9.7 0.917
Male gender, n (%) 7 (70%) 14 (45%) 0.172
Body mass index (kg/m2) 28 ± 5.1 28 ± 4.0 0.580
BSA (m2) 2 ± 0.3 2 ± 0.2 0.580
Prothesis size [mm] 24 ± 2 23 ± 2 0.247
Biological prosthesis, n (%) 10 (100%) 29 (94%) 0.410
Prosthesis type Medtronic biological, n (%) 1 (10%) 0 (0%) 0.075
Prosthesis type Medtronic mechanical, n (%) 0 (0%) 1 (3%) 0.565
Prosthesis type Edwards, n (%) 2 (20%) 7 (23%) 0.864
Prosthesis type SJM regent, n (%) 0 (0%) 1 (3%) 0.565
Prosthesis type Trifecta, n (%) 5 (50%) 16 (52%) 0.929
Prosthesis type CE Perimount Magna Ease, n (%) 2 (20%) 6 (19%) 0.964
Risk factors
 Bicuspid aortic valve, n (%) 8 (80%) 23 (74%) 0.710
 Dyslipidaemia, n (%) 7 (70%) 13 (42%) 0.123
 Diabetes mellitus, n (%) 2 (20%) 2 (6%) 0.209
 Arterial hypertension, n (%) 8 (80%) 21 (68%) 0.459
 CCS III-VI, n (%) 1 (10%) 2 (6%) 0.708
 NYHA III-IV, n [%] 5 (50%) 13 (42%) 0.655
Medical Treatment
 Betablocker, n (%) 4 (40%) 13 (42%) 0.914
 Calcium antagonist, n (%) 1 (10%) 3 (10%) 0.976
 Diuretics, n (%) 3 (30%) 8 (26%) 0.795
 ARB, n (%) 3 (30%) 6 (19%) 0.479
 ACE-I, n (%) 4 (40%) 7 (23%) 0.280
  1. BSA body surface area, CCS Canadian Cardiovascular Society, NYHA New York Heart Association, ARB angiotensin receptor blocker, ACE-I Angiotensin converting enzyme inhibitor